A Study of SYS6010 Combined With Enlonstobart in Patients With Previously Systemic Treatment-Naive R/M Nasopharyngeal Carcinoma

This is a randomized, open-label, multicenter phase Ⅲ trial to evaluate the efficacy and safety of SYS6010 combined with Enlonstobart injection versus Tislelizumab combined with chemotherapy (gemcitabine plus cisplatin) in patients with previously systemic treatment-naive recurrent or metastatic nasopharyngeal carcinoma

Trial Details

NCT ID
NCT07925021
Phase
PHASE3
Sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Status
RECRUITING
Cancer Type
Head and Neck Cancer
Interventions
  • SYS6010 combined with Enlonstobart
  • Tislelizumab combined with chemotherapy
Locations (sample)
  • Guangzhou, Guangzhou, China|23.11667,113.25

Key Eligibility Criteria

  • Female participants aged ≥ 18 years (as of the date of signed informed consent).
  • Histologically confirmed recurrent or metastatic nasopharyngeal carcinoma, with no prior systemic therapy for recurrent or metastatic nasopharyngea…
  • For recurrent nasopharyngeal carcinoma: the disease is currently not eligible for local or curative-intent treatment, and the interval from complet…
  • Willing to provide tumor tissue samples for testing of EGFR protein and PD-L1 expression. If sample collection is not feasible for certain reasons,…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Head and Neck Cancer Trials on Trialify →